ARTICLE | Product Development
TYK2 best-in-class battleground expands with InnoCare data
In BioCentury’s latest Clinical Report: Sage misses in early Alzheimer’s, and a Phase III setback for J&J’s bladder cancer delivery device
October 9, 2024 11:30 PM UTC
TYK2 inhibitors are emerging as a battleground for best-in-class innovation as the list of new therapies outperforming first-in-class product Sotyktu continues to grow.
Chinese biotech InnoCare Pharma Ltd. (HKEX:9969; Shanghai:688428) is the latest company to unveil Phase II data from a TYK2 class member, showing again that it’s possible to achieve 75% skin clearance in more than two-thirds of psoriasis patients with an oral therapy...